Physicochemical convergence in antibody CDR3-VH repertoires recognizing phosphorothioate-modified oligonucleotides backbone - Takeaways - MDSpire

Physicochemical convergence in antibody CDR3-VH repertoires recognizing phosphorothioate-modified oligonucleotides backbone

  • By

  • Riccardo Galasso

  • Francesco Coppolino

  • Alessia Berbiglia

  • Grete Francesca Privitera

  • Agata Famà

  • Giuseppe Valerio De Gaetano

  • Germana Lentini

  • Concetta Beninati

  • May 29, 2026

  • 0 min

Share

  • 1

    The study investigates antibody binders against phosphorothioate-modified antisense oligonucleotides using next-generation sequencing and phage display.

  • 2

    Deep sequencing revealed reduced repertoire diversity and clonal dominance from Round 1 to Round 2 of selection against PS-ASOs.

  • 3

    A shared set of 113 CDR3-VH clonotypes was identified, displaying increased positive charge and specific physicochemical properties.

  • 4

    The scFv clone 12F2 showed preferential binding to PS-ASOs and produced detectable signals in ASO-treated cells.

  • 5

    The findings suggest that early selection against PS-ASOs leads to reproducible repertoire focusing and physicochemical convergence.

Original Source(s)

Physicochemical convergence in antibody CDR3-VH repertoires recognizing phosphorothioate-modified oligonucleotides backbone

  • by Riccardo Galasso, Francesco Coppolino, Alessia Berbiglia, Grete Francesca Privitera, Agata Famà, Giuseppe Valerio De Gaetano, Germana Lentini, Concetta Beninati

  • May 29, 2026

Related Content

Can Proteomics Refine Lung Screening?

Proteomic biomarkers improve short-term lung cancer risk assessment.

Troponin Testing and Early MI Discharge

Sixth-generation high-sensitivity cardiac troponin T assay classifies more patients below a low-risk threshold at presentation.

Leading Pathology’s Digital Evolution

Sitting Down With… Liron Pantanowitz, Chair and Professor of Pathology at University of Pittsburgh